Haplo HCT vs Haplo-cord HCT for Patients With AML

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
Patients who have acute myeloid leukemia and will undergo haplo‐identical donor hematopoeitic cell transplantation (haplo HCT) are potential candidates of this trial. Participants will randomized into two arms: Arm A will undergo a typical haplo HCT, while Arm B will receive an coinfusion of an unrelated cord blood unit (haplo‐cord HCT) in addition to Arm A. Progression‐free survival, overall survival, cumulative incidence of relapse and nonrelapse mortality will be recorded as endpoints.
Epistemonikos ID: 70a1a447c235334ca445906b3bf6fbe113890ef2
First added on: May 21, 2024